FDA issued a Complete Response Letter (CRL) regarding Disc Medicine, Inc.'s bitopertin program.
4 reports, 3 independent
Updated Oct 1
Gone quiet
- Reports
- 4
- Developments
- 3
- Repetition
- 25%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA issued a Complete Response Letter (CRL) regarding Disc Medicine, Inc.'s bitopertin program.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Disc Medicine secured global rights to bitopertin under a license agreement from Roche.1 source
FDA rejects Disc Medicine's bitopertin program; shareholders file securities claims.1 source
FDA rejected Disc Medicine's bitopertin program via CRL.1 source